chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Got COVID; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Got COVID) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced COVID-19 (Got COVID). At the time of the report, COVID-19 (Got COVID) outcome was unknown.            No concomitant medication was provided by the reporter.  It was reported that patient had a Moderna shot and then a booster shot and then got the COVID reporter wanted to know that if patient can get vaccinated with the second booster.  No treatment medication was provided by the reporter.  Company Comment: This is a spontaneous case concerning a female patient of an unknown age with no reported medical history, who experienced the unexpected non-serious adverse event of special interest, COVID-19. The event occurred on an unknown date after receiving a dose (the event may have occurred after the booster dose of mRNA-1273 as stated that the patient had Moderna shot then Booster shot then got COVID) of mRNA-1273 Vaccine. No clinical or treatment details were given. It was reported that the outcome of the event was unknown. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.; Sender's Comments: This is a spontaneous case concerning a female patient of an unknown age with no reported medical history, who experienced the unexpected non-serious adverse event of special interest, COVID-19. The event occurred on an unknown date after receiving a dose (the event may have occurred after the booster dose of mRNA-1273 as stated that the patient had Moderna shot then Booster shot then got COVID) of mRNA-1273 Vaccine. No clinical or treatment details were given. It was reported that the outcome of the event was unknown. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.
Chills progressing from late afternoon into early evening. C/o of nausea, muscle cramping.
Narrative:  was sent to ER due to allergic reaction wheals/urticaria to the covid shot
THRUSH IN MOUTH; This spontaneous report received from a patient concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number: not reported) dose was not reported, administered on 31-MAR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On 2021, the subject experienced thrush in mouth. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of thrush in mouth was not reported. This report was non-serious.
have not gotten second dose; fever; tiredness; muscle pain on my arm / body aches; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (muscle pain on my arm / body aches), PYREXIA (fever), FATIGUE (tiredness) and PRODUCT DOSE OMISSION ISSUE (have not gotten second dose) in a 45-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037A21B) for COVID-19 vaccination.     No Medical History information was reported.    On 06-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 06-Apr-2021, the patient experienced MYALGIA (muscle pain on my arm / body aches). On 07-Apr-2021, the patient experienced PYREXIA (fever) and FATIGUE (tiredness). On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (have not gotten second dose). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. On 08-Apr-2021, MYALGIA (muscle pain on my arm / body aches), PYREXIA (fever) and FATIGUE (tiredness) had resolved. At the time of the report, PRODUCT DOSE OMISSION ISSUE (have not gotten second dose) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication details was reported.
Blood in stool began to be observed. This continued and did not stop.  It was a small amount of blood and it was mixed into the stool. Also mucus began to become visible in the stool.
Mother called on 8/17/15 to report pt. has chickenpox as well as pt's father. Mother indicated vesicles erupted on 8/11/15, and began on each side of her thorax. At present they are crusting over. Indicates pt. has no other symptoms. Mother indicated she has approx 50 vesicles (spots). Mother would not count. Vesicles on entire body of pt. and itch. Pt went to MD on 8/17/15. MD ordered Acyclovir 200mg 5ml 10ml 4/d when awake. Note indicated mild chickenpox.
I20.0 UNSTABLE ANGINA 4/19/2023 UNSTABLE ANGINA
Pain in center of chest; Hard to breathe; Tingling in scalp left side mainly; Headaches and sudden head pain; Exhaustian; Heavy chest; This is a spontaneous report from a contactable consumer, the patient. A 62-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729) via an unspecified route of administration in the left arm on 15Apr2021 at 14:00 (at the age of 62-years-old) as a single dose for COVID-19 immunisation. Medical history included psoriatic arthritis and high blood pressure. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included lisinopril (MANUFACTURER UNKNOWN), atenolol (MANUFACTURER UNKNOWN), colecalciferol (D-3) and ascorbic acid (VITAMIN C); all from an unknown date for an unknown indication and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received paracetamol, oxycodone hydrochloride (PERCOCET) and experienced drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730) via an unspecified route of administration in the right arm on 25Mar2021 at 14:15 (at the age of 62-years-old) as a single dose for COVID-19 immunisation. On 25Apr2021, the patient experienced heavy chest and pain in center of chest, hard to breathe, tingling in scalp left side mainly, headaches, sudden head pain and exhaustion. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event heavy chest, pain in center of chest, hard to breath, tingling in scalp left side, headaches, sudden head pain and exhaustion was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Chest pains; missed dose; A spontaneous report was received from a consumer concerning a male patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced hospitalization with chest pain and missed dose.   The patient's medical history was not provided. No concomitant was provided.  On 09 Feb 2021, prior to the onset of the events, the patient received their first of two planned doses of mRNA-1273 (Lot number: 027L20A) intramuscularly on his left arm for prophylaxis of COVID-19 infection.   On 04/Mar/20201 patient reported that he was admitted in hospital with chest pain. Patient reports that he had no symptoms after the Moderna COVID-19, but will be unable to make his second vaccine appointment.   Action taken with mRNA-1273 in response to the events was not reported.   The outcome of the event:, chest pain,  was considered unknown/not reported  The outcome of the event, missed dose, was considered recovered/resolved on an unknown date.; Reporter's Comments: Very limited information regarding the events has been provided at this time. Company assessed the events to be unlikely related to company product.
This spontaneous report as received from a pharmacist refers to a patient of an unknown age and gender. The patient's concurrent conditions, medical history, historical drugs and concomitant therapies were not reported. On an unknown date, the patient was vaccinated with one dose of ZOSTAVAX, and on 08-OCT-2017, the patient received a second dose of ZOSTAVAX 19400 pfu (dose, route, lot number and expiration date were not reported) both for prophylaxis (extra dose administered). Other suspect therapies included sterile diluent (MERCK STERILE DILUENT). No adverse events were reported.
Around 3:15-3:20pm, after patient had received her first dose of Pfizer Covid vaccine, she was reading paperwork about her vaccine and started to feel anxious. her vision and hearing started to be affected/muffled and she came up to the counter to let the pharmacy staff know. After doing so, she did not make it back to her chair before falling to the ground. Rx technician witnessed this. 911 was called by front store management and EMS was en route. Patient states she may have lost consciousness for a few seconds but remembers being helped up and seated in chair. 911 operator instructed pharmacist not to administer epinephrine. A short time later, the patient vomited. With her permission, her father was informed and left work to meet her at the pharmacy. She contacted him when EMS arrived to discuss whether she should go to the hospital as she was feeling much better. She declined going to hospital and was monitored by pharmacy staff until her father arrived about an hour later.
Office Visit 3/12/2021 WellSpan Family Medicine - Crossroads  DO Family Medicine COVID-19 virus infection +10 more Dx Fever  Reason for Visit Progress Notes , DO (Physician) ? ? Family Medicine ? ? Encounter Date: 3/12/2021 ? ? Signed Expand AllCollapse All    Office Visit     Assessment/Plan    Diagnoses and all orders for this visit:   COVID-19 virus infection   Suspected COVID-19 virus infection -     POCT COVID-19 Antigen   Mild intermittent asthma without complication   Essential hypertension with goal blood pressure less than 130/80   Coronary artery disease involving native coronary artery of native heart without angina pectoris   Paroxysmal atrial fibrillation (CMS/HCC);Gastroesophageal reflux disease without esophagitis;Irritable bowel syndrome with diarrhea;Hyperlipidemia with target LDL less than 70;Chronic anticoagulation;Close exposure to COVID-19 virus;covid Ag is positive;MAB tx  Clinical Support 3/12/2021 WellSpan Infusion Center - Ephrata RN COVID-19 virus infection Dx Medication Infusion  Reason for Visit Progress Notes RN (Registered Nurse) ? ? Encounter Date: 3/12/2021 ? ? Signed    arrived to the ambulatory infusion site with his wife via car. Reports intermittent fatigue, dizziness, diarrhea, nausea, dry nonproductive cough, and shortness of breath,    stated he discussed Bamlanivimab infusion and associates risks with his doctor prior to this infusion. Reports all question were answered to his statisfaction. Denies any concerns or needs at this time.
44-year old  patient was administered with a dose in his right arm; This case was reported by a physician via call center representative and described the occurrence of inappropriate age at vaccine administration in a 44-year-old male patient who received Herpes zoster (Shingrix) (batch number 3BD53, expiry date unknown) and (batch number 53LK5, expiry date unknown) for prophylaxis.   Concomitant products included DIPHTHERIA VACCINE TOXOID + PERTUSSIS VACCINE ACELLULAR + TETANUS VACCINE TOXOID (DTPA VACCINE).   On 17th June 2022, the patient received Shingrix. On an unknown date, the dose was an unknown dose. On 17th June 2022, unknown after receiving Shingrix, the patient experienced inappropriate age at vaccine administration. On an unknown date, the outcome of the inappropriate age at vaccine administration was unknown.   Additional Information: GSK Receipt Date: 25-JUN-2022 and 27-JUN-2022 Reporter's comment: This adverse event was reported and submitted by a GlaxoSmithKline sales representative. This may be a duplicate case since the sales representative might have already reported. This adverse event was late because it came in over the weekend. Due to medical information guidelines, this adverse event was reported even when another GlaxoSmithKline representative was first to hear about it. Doctor stated that a colleague at her's mistakenly administered a Shingrix vaccine to a 44-year old patient in his right arm. The patient was not immune compromised.  The patient also received a Tdap in his left arm on the same visit. The doctor thought that these lot numbers were for both Shingrix components, not the Tdap vaccine).  The patient did not experience any adverse Events. The reporter consented to follow-up. Additional Supportive Information: The 44 years old patient received dose of Shingrix vaccine, which led to Inappropriate age at vaccine administration.
Information has been received from a lawyer and a consumer regarding a case in litigation concerning a male patient (age unknown). The patient's medical history, concurrent conditions and concomitant medications were not provided. The patient's healthcare providers recommended and/or prescribed ZOSTAVAX to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. In 2013 the patient's healthcare provider administered the ZOSTAVAX vaccine to the patient. The patient was inoculated with the ZOSTAVAX vaccine to obtain permanent prevention and protection against shingles and zoster-related conditions. In 2014, the patient was treated by a healthcare provider for shingles. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with ZOSTAVAX vaccine, and suffered serious physical, emotional and economic damages as a result of the patient's injuries. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; lost wages; loss of earnings capacity; and other losses and damages. Additional information has been requested.
Pt received DTAP and should have received TDAP No s/s adverse reaction immediately following, nor 1 week following.
Patient felt "funny" a few minutes post vaccine but couldn't describe what that meant. Vital signs were stable and patient was observed for 55 minutes. 128/64, pulse 84 resp 24. Vaccine was given at 11:50, vitals at 12:20, left clinic at 12:45. At 5pm patient began wheezing and feeling short of breath. PCP ordered prednisone, Benadryl and Pepcid. Wheezing has improved some today. Today patient has fatigue, body aches and fever.
Felt sharp pain under jaw, then facial numbness. Then quickly developed facial swelling, left eye swelling and tongue swelling. Then felt like throat closing up within 7 minutes of receiving vaccine. Received vaccine in the clinic, was transported to Emergency Room. In ER received Epinephrine, steroids, Benadryl and Pepcid.
fainting spell, unresponsive x 1 min; incontinent of urine; stiffness in extremities;
LIGHT HEAD; SORE ARM; This spontaneous report received from a patient via a company representative concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unk) dose, start therapy date were not reported for prophylactic vaccination. No concomitant medications were reported.  On an unspecified date, the subject experienced sore arm, and light head. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from sore arm, and light head. This report was non-serious.
Patient signed up to receive the flu and covid shot.  We confirmed she was receiving the two vaccinations prior to administering.  The following day patient called and stated she received her flu shot five days prior at her MD office.  Patient received two doses of high dose flu vaccination within 5 days.  We confirmed with our corporate office that Patient will be fine and to reach out with any additional questions or concerns.
A  few days after my first shot my heart was fluttering quite a bit.  It lasted quite a few weeks but it wasn't super life changing just something I noticed. I was breastfeeding my 5 month old at the time. I postponed my second shot until 6 weeks and within 4 days of my second shot my heart was fluttering /pounding every day several times a day. It was hard not to ignore so I scheduled a Dr apt with a local clinic and they did blood work and found my TSH to be 0.00.  they did other blood work and found that I didn't have graves etc. But my T3 and T4 thyroid tests were elevated as well.  The Dr there advised I file a Vaers report and referred me to an endocrinologist.  My endocrinologist did more bloodwork and found that he believes it is thyroiditis.
I got the flu every time I got the shot no more for me; Initial information received on 27-Oct-2020 regarding an unsolicited valid non-serious social media case received from a non-healthcare professional (consumer) via social media.  This case involved a patient with unknown age and gender who got the flu every time patient got the shot (Influenza) after receiving INFLUENZA VACCINE.  Medical history, medical treatment(s), vaccination(s), concomitant medication(s) and family history were not provided.  On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number and expiry date were not reported) via unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, unknown latency, the patient developed flu every time patient got the shot (Influenza).  No relevant laboratory details were provided.  It was not reported if the patient received a corrective treatment.  Outcome was reported as unknown for the event of influenza.  There will be no information available on the batch number for this case.
p/vax pt exp vision tunneled & pt fainted; syncope; c/o jaw feeling like it was going to lock open;c/o stomach upset; unusual hearing; rash on arms
Pt c/o with shortness of breath. Having fevers of 101, nonproductive cough, diarrhea, headache.   Pt discharged on 7/21/2021
TIRED; MUSCLE ACHES; This spontaneous report received from a patient concerned a 62 year old male. The patient's weight was 170 pounds, and height was 68 inches. The patient's past medical history included bladder removal, and polyp removed from colon, and concurrent conditions included alcohol consumer, and non-smoker, and other pre-existing medical conditions included no known allergies and illicit drug use.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 203A21A, and batch number: 203A21A expiry: 23-JUN-2021) dose was not reported, administered on 24-MAY-2021 for prophylactic vaccination. No concomitant medications were reported. On 24-MAY-2021, the subject experienced tired. On 24-MAY-2021, the subject experienced muscle aches. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from tired, and muscle aches. This report was non-serious.
Next morning I had a swollen arm and redness at the injection site and  could not move my arm.  That day and next day I had a constant fever which went up to +99 F and felt fatigue.  Redness mostly disappeared but after a week clearly see redness at the injection site and circular redness (at least 5 cm diameter) and swollen lymp nodes  under arm of left arm and especially at night it makes me wake up,  And on 9th day, I had a slight fever again.
Patient was given 3 injections (1) Tdap (2) Varicella (3) MCV4 .5 mL IM; Varicella .5 mL SQ on 11-15-10. Pt. left and was gone about 15 mins. Mother came back with the pt. Patient was c/o of itching and difficulty in breathing. Dr was called. Per doctors orders ambulance was called. Pt. was checked on by phone. She was doing good.
The vial was first punctured on 08-Apr-2022 and administered on 11-Apr-2022. The vial was stored in refrigerator post puncture.; Administer a vaccine after 12 hours of first puncture; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Administer a vaccine after 12 hours of first puncture) and PRODUCT STORAGE ERROR (The vial was first punctured on 08-Apr-2022 and administered on 11-Apr-2022. The vial was stored in refrigerator post puncture.) in a 61-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 002m21a, 030b21a and 042b21a) for COVID-19 vaccination.     The patient allergies (medications, food and other products) was reported as unknown. The patient never had COVID positive test or diagnosed.  Concurrent medical conditions included Chronic kidney disease (Recent change in status such as improvement or worsening was unknown.).   On 20-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 18-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 11-Apr-2022 at 1:30 PM, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 11-Apr-2022 at 1:30 PM,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (Administer a vaccine after 12 hours of first puncture). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (The vial was first punctured on 08-Apr-2022 and administered on 11-Apr-2022. The vial was stored in refrigerator post puncture.). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Administer a vaccine after 12 hours of first puncture) and PRODUCT STORAGE ERROR (The vial was first punctured on 08-Apr-2022 and administered on 11-Apr-2022. The vial was stored in refrigerator post puncture.) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication was reported.  No other vaccines were given within 1 month prior to Moderna COVID-19 vaccine. The vaccine was first punctured on 08-Apr-2022 at 9:38AM. The vial was stored in refrigerator post puncture.  It was reported that 8 minutes total the vial was exposed to room temperature range (8° to 25°C= 46° to 77°F). The vial was not exposed to room temperature for >24 hours. The vial did not undergo any temperature excursions. Adverse event cause patient to seek medical care (office visit, Urgent care, ER, hospitalized) was reported as unknown.  No treatment medication was reported.
Mother states day after immunizations give, patient complained of earache.  Mother noticed swelling behind the ear patient also had diarrhea.  Patient taken to clinic 08/08/2003.  Mother states patient was given antibiotic injections and steroid.  States was diagnosed with parotitis 08/18/2003: Clinic diagnosed coincidental viral illness per phone call from clinic staff.